Atara Biotherapeutics (ATRA) Total Liabilities (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Total Liabilities came in at $57.3 million in Q1 2026, down 51.06% YoY from $117.1 million in Q1 2025, and down 2.43% on a QoQ basis from $58.7 million in Q4 2025.
Atara Biotherapeutics (ATRA) Total Liabilities (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Total Liabilities data on file, last reported at $57.3 million in Q1 2026.
- Quarterly Total Liabilities fell 51.06% year-over-year to $57.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.3 million (down 51.06% YoY) and the FY2025 annual result came in at $58.7 million, down 71.54% from the prior year.
- Total Liabilities declined to $57.3 million in Q1 2026, from $58.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $264.7 million in Q4 2023 to a low of $57.3 million in Q1 2026.
- A 5-year average of $180.4 million and a median of $206.4 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 42.62% — and 2025, when it tumbled 71.54%.
- Tracing ATRA's Total Liabilities over 5 years: stood at $249.8 million in 2022, then advanced by 5.99% to $264.7 million in 2023, then fell by 22.04% to $206.4 million in 2024, then plunged by 71.54% to $58.7 million in 2025, then declined by 2.43% to $57.3 million in 2026.
- The last three Total Liabilities figures came in at $57.3 million (Q1 2026), $58.7 million (Q4 2025), and $66.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | 58.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.02 Mn |
| Mar 31, 2026 | 57.31 Mn |
| Dec 31, 2025 | 58.74 Mn |
| Sep 30, 2025 | 66.80 Mn |
| Jun 30, 2025 | 71.94 Mn |
| Mar 31, 2025 | 117.11 Mn |
| Dec 31, 2024 | 206.38 Mn |
| Sep 30, 2024 | 233.25 Mn |
| Jun 30, 2024 | 228.15 Mn |
| Mar 31, 2024 | 263.58 Mn |
| Dec 31, 2023 | 264.74 Mn |
| Sep 30, 2023 | 239.63 Mn |
| Jun 30, 2023 | 238.99 Mn |
| Mar 31, 2023 | 237.12 Mn |
| Dec 31, 2022 | 249.78 Mn |
| Sep 30, 2022 | 181.20 Mn |
| Jun 30, 2022 | 178.64 Mn |
| Mar 31, 2022 | 172.96 Mn |
| Dec 31, 2021 | 188.51 Mn |
| Sep 30, 2021 | 139.78 Mn |